AUPH CIK: 1600620

Aurinia Pharmaceuticals Inc.

  • Canada
  • Healthcare
  • Biotech
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25

Assets

(positive)
Change from FY21 to FY25
millions USD
FY21:
513
FY22:
443
FY23:
425
FY24:
447
FY25:
492
(positive)
Change from FY21 to FY25
millions USD
FY21:
30.0
FY22:
28.3
FY23:
123
FY24:
104
FY25:
260
Total assets
Change from FY21 to FY25
millions USD
FY21:
543
FY22:
471
FY23:
548
FY24:
551
FY25:
752

Liabilities & Equity

(negative)
Change from FY21 to FY25
millions USD
FY21:
40.6
FY22:
46.1
FY23:
77.2
FY24:
97.8
FY25:
93.7
(negative)
Change from FY21 to FY25
millions USD
FY21:
23.6
FY22:
19.3
FY23:
92.9
FY24:
75.4
FY25:
76.5
(positive)
Change from FY21 to FY25
millions USD
FY21:
479
FY22:
405
FY23:
378
FY24:
377
FY25:
581
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
543
FY22:
471
FY23:
548
FY24:
551
FY25:
752

All amounts in millions USD Data sources:SEC EDGARTwelve Data